Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=3&sort=-funder
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-funder", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=-funder", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=4&sort=-funder", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=2&sort=-funder" }, "data": [ { "type": "Grant", "id": "2721", "attributes": { "award_id": "3U54MD007586-35S5", "title": "The RCMI Program in Health Disparities at Meharry Medical College - Supplement", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 8024, "first_name": "Rina", "last_name": "Das", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1997-09-30", "end_date": "2022-09-20", "award_amount": 363750, "principal_investigator": { "id": 8025, "first_name": "Samuel E", "last_name": "Adunyah", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [ { "id": 8026, "first_name": "JAMES E", "last_name": "HILDRETH", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 938, "ror": "https://ror.org/00k63dq23", "name": "Meharry Medical College", "address": "", "city": "", "state": "TN", "zip": "", "country": "United States", "approved": true }, "abstract": "Meharry Medical College (MMC) is a Historically Black College/University located in Nashville Tennessee and the first medical school for African Americans in the South. It has a School of Medicine, School of Dentistry, and School of Graduate Studies & Research. In February 2021, it established a new fourth school, the School of Applied Computational Sciences (SACS), to provide academic training in data science and computing-related research on a variety of areas including medical, social, and environmental issues and trends that impact the health of minority and underserved populations. The Research Centers in Minority Institutions (RCMI) Program at MMC (in Health Disparities Research, RHDR@MMC) is a long-term NIMHD- funded endeavor that enables high quality basic, behavioral, and clinical research to eliminate health disparities. Our RCMI U54 grant supports health disparities research in many diseases including cardiovascular diseases, cancer, diabetes, HIV/AIDS and neurological diseases that disproportionally affect non-Hispanic Black population in the US. With the great potential of data science to transform industries, health care, and scientific discovery, this administrative supplement seeks to enhance the data science capacity of the RHDR@MMC program and foster collaborations between RCMI researchers and data scientists, to enable the RCMI investigators to assess and analyze big health sciences data to enhance the overall productivity of the RCMI program as well as contribute to addressing health disparities. Specifically, this supplement award will help create a data science task force for this project, identify data science needs of the RCMI researchers at Meharry, and foster collaborations between them and the data science experts in SACS which will include the development of a joint RCMI/SACS Workshop. This will enable SACS to provide RCMI researchers with much needed data science expertise and resources for study design, data infrastructure, data collection, data engineering, health informatics, and machine learning techniques, to enhance research outcome as well as the cooperation among investigators from different domains. It will enable the RCMI researchers of all levels to better address the challenges in their health disparities research. With this award, we expect that the RHDR@MMC program will be greatly empowered to advance research on minority health and health disparities.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10577", "attributes": { "award_id": "1C06OD034103-01", "title": "Expansion and modification of animal housing and support spaces to increase production of the NIH U42 supported pigtailed macaque colony at Johns Hopkins University", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 11602, "first_name": "GUANGHU", "last_name": "Wang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-20", "end_date": "2027-05-31", "award_amount": 5500152, "principal_investigator": { "id": 24155, "first_name": "Eric Kenneth", "last_name": "Hutchinson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "In the face of well-documented ongoing shortages of nonhuman primates for biomedical research and evidence that they may be a unique model for COVID-19, it is no surprise that the demand for pigtail macaques remains strong and continues to climb. Since the onset of NIH- support in 2006, the JHU pigtail macaque colony has provided 313 animals for biomedical research, the vast majority of which was HIV/AIDS related. With 172 of those animals (55%) going to NIH funded investigators at institutions outside of JHU, we have established our colony as an important national resource of this valuable animal model. To meet the growing need for pigtail macaques in biomedical research, we have developed a plan to significantly increase the number of animals that we can house at the JHU Research Farm and further refine our behavioral management of this breeding colony to improve productivity. First, we propose to construct an addition to the existing Building 12, significantly expanding animal housing and support spaces. This new construction will include animal housing space and innovative caging for 120 additional animals across 6 harems. This addition will also house dedicated support spaces, including an operating room, radiology room, flex holding space for convalescing or pre- sale animals, and a cage washing area, along with personnel spaces such as a staff locker room with connected showers, bathroom, laundry, and PPE donning/doffing area. Second, we propose to install underground fiber optic cable and other network infrastructure to connect the JHU Research Farm facilities to high-speed internet. This project will allow us to fully leverage the soon-to-be-installed JHU-funded upgrades to 1) security and 2) electronic animal health and behavior records. If this proposal is successful, we will better serve the NIH-funded research community that relies on primate models in two key ways: 1) we will increase the number of animals available to researchers and 2) we will evaluate the novel husbandry and behavioral management features designed into the new building and share our findings with NIH-funded nonhuman primate researchers and other national breeding centers.", "keywords": [ "AIDS/HIV problem", "Animal Housing", "Animal Model", "Animals", "Area", "Behavioral", "Biomedical Research", "Breeding", "COVID-19", "Communities", "Farm", "Fiber Optics", "Funding", "Health behavior", "Human Resources", "Institution", "Internet", "Macaca nemestrina", "Modeling", "Modification", "Network Infrastructure", "Operating Rooms", "Primates", "Production", "Productivity", "Radiology Specialty", "Records", "Research", "Research Personnel", "Resources", "Sales", "Security", "Speed", "United States National Institutes of Health", "Universities", "design", "improved", "innovation", "nonhuman primate", "novel" ], "approved": true } }, { "type": "Grant", "id": "10617", "attributes": { "award_id": "1R35GM146861-01", "title": "Molecular Mechanisms of Programmed Necrosis Execution", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 24077, "first_name": "Baishali", "last_name": "Maskeri", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-20", "end_date": "2027-07-31", "award_amount": 410000, "principal_investigator": { "id": 26659, "first_name": "Ayaz", "last_name": "Najafov", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1215, "ror": "", "name": "UT SOUTHWESTERN MEDICAL CENTER", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "Necroptosis is a caspase-independent type of programmed necrosis. The activation of the necroptosis signaling cascade is implicated in the pathogenesis of various human diseases, including cancer, inflammatory bowel disease, liver injury, pancreatitis, neurodegenerative disorders, and a diverse range of viral, bacterial, and fungal infections, including SARS-CoV-2. The necroptosis signaling cascade is mediated by the sequential activation of RIPK1 and RIPK3 kinases downstream of pro-inflammatory ligands such as TNF or microbe-associated molecules. MLKL is a pseudokinase that tetramerizes upon phosphorylation by RIPK3 to form water-permeable pores that drive cell membrane rupture. This pore formation stage leads to the necrotic phenotype of necroptosis. It is also a critical point of cell fate determination, as necroptosis execution can be halted and reversed at the MLKL stage. The mechanisms regulating MLKL activation and execution of this type of programmed necrosis are poorly understood. Here, we will fill in the gaps of our understanding of the molecular mechanisms that regulate MLKL activation, tetramerization, and execution of necroptotic cell death via phosphorylation and ubiquitination. We aim to determine the mechanistic roles of the MLKL post-translational modification events in promoting or suppressing MLKL tetramerization and identify the enzymes regulating MLKL-driven necrotic cell death via these events. We also aim to determine which structural factors are required downstream of MLKL to execute the necroptotic cell death. Finally, to validate the roles of these enzymes and factors in mediating necroptosis in vivo, we will test how their genetic knockouts affect sensitivity to Vaccinia virus infection, contributing to the future development of strategies for enhancing host anti-viral response. Overall, this project will significantly expand our understanding of the cellular signaling mechanisms upstream and downstream of MLKL at the necroptosis execution stage and pave the way for future anti-microbial therapies, as well as treatments for diseases that involve necroptosis execution.", "keywords": [ "2019-nCoV", "Affect", "Antiviral Response", "Bacterial Infections", "Caspase", "Cell Death", "Cell membrane", "Cells", "Development", "Disease", "Enzymes", "Event", "Future", "Genetic", "Inflammatory", "Inflammatory Bowel Diseases", "Knock-out", "Ligands", "Malignant Neoplasms", "Mediating", "Microbe", "Molecular", "Mycoses", "Necrosis", "Neurodegenerative Disorders", "Pancreatitis", "Pathogenesis", "Permeability", "Phenotype", "Phosphorylation", "Phosphotransferases", "Post-Translational Protein Processing", "RIPK1 gene", "RIPK3 gene", "Regulation", "Role", "Rupture", "Signal Transduction", "TNF gene", "Testing", "Ubiquitination", "Vaccinia virus", "Virus Diseases", "Water", "Work", "antimicrobial", "human disease", "in vivo", "liver injury" ], "approved": true } }, { "type": "Grant", "id": "10609", "attributes": { "award_id": "1R01MD018206-01", "title": "CRISOL Mente: A Multilevel Community Intervention to Reduce Mental Health Disparities Among Latinos", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 6025, "first_name": "Crystal", "last_name": "Barksdale", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-19", "end_date": "2027-05-31", "award_amount": 1119618, "principal_investigator": { "id": 26650, "first_name": "Mariana", "last_name": "Lazo Elizondo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 23052, "first_name": "Ana P", "last_name": "Martinez-Donate", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 377, "ror": "https://ror.org/04bdffz58", "name": "Drexel University", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 377, "ror": "https://ror.org/04bdffz58", "name": "Drexel University", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Latinos in the U.S. experience significant disparities in access to mental health services due to lack of health insurance, cost of services, limited awareness of mental health resources, mental health stigma, and fear of deportation. Limited English proficiency coupled with an acute lack of bilingual and culturally competent providers further impede Latinos’ adequate access to quality mental health services. The COVID-19 pandemic has only amplified the need for mental health care and exacerbated mental health disparities for Latino communities, making it urgent to identify low-cost, effective strategies to reduce these gaps. This 5-year project seeks to develop and test a multi-level, community intervention to improve mental health outcomes and promote access to culturally appropriate mental health treatment for Latino communities in Philadelphia. CRISOL Mente will include components at various levels of the socio-ecological model: a clinic-based, stepped-care program relying on Latino lay health workers (LHW) for the delivery of mental health services (Aim 1), outreach and education activities to reduce mental health stigma in the community (Aim 2), and efforts to strengthen Latino-serving organizations’ capacity to address mental health and other syndemic conditions contributing to untreated mental health among Latinos (Aim 3). To improve mental health symptoms and engagement in care, we will recruit, train and supervise a cohort of Latino LHW who will be embedded into two Latino-serving clinics, extending the reach and effectiveness of the clinics’ mental health services. We will compare the impact of three different levels of LHW involvement: a) community outreach/navigation (i.e. screening and referral of community members); b) auxiliary care (i.e. screening, referral, and help overcoming barriers to better mental health); and c) task shifting (i.e. screening, referral, assistance, and supervised delivery of basic mental health treatment). The LHWs will also conduct outreach/education activities in the community (e.g. radio talks, info sessions, tables in community venues) to reduce mental health stigma. Our experienced and largely Latino community-academic research team will also engage in capacity building activities (i.e. monthly town halls, annual retreats, weekly newsletters, provision of trainings and technical support) with the Latino Health Collective, a coalition of Latino-serving organizations. Using mixed-methods and the RE-AIM framework, CRISOL Mente’s impact will be evaluated with clinical data, baseline and 6-month patient survey data (N=200 from each level of LHW involvement), and qualitative interviews with community members (N=30) referred to mental health services by the LHW (Aim 1); pre/post mental health stigma data from two respondent driven sampling (RDS) surveys of Latinos (N=400 each) conducted in 2022 (preliminary study) and in 2027 (Aim 2); community capacity indicators from three surveys of Latino-serving organizations conducted in 2019, 2021 (preliminary studies) and 2027, and key informant interviews (KII) with Latino-serving providers (N=30) in 2019 (preliminary study) and 2027 (Aim 3).", "keywords": [ "Acute", "Address", "Adherence", "Advocacy", "Awareness", "COVID-19 pandemic", "Caring", "Client", "Clinic", "Clinical Data", "Communication", "Communities", "Community Outreach", "Community Surveys", "Complex", "Coupled", "Data", "Development", "Discrimination", "Economics", "Education", "Education and Outreach", "Educational Background", "Effectiveness", "Evaluation", "Evidence based treatment", "Fright", "Health", "Health Insurance", "Health Resources", "Health Services Accessibility", "Healthcare", "Immigrant", "Intervention", "Interview", "Language", "Latina", "Latino", "Latino Population", "Legal", "Limited English Proficiency", "Linguistics", "Mental Depression", "Mental Health", "Mental Health Services", "Mental disorders", "Methods", "Modeling", "Newsletter", "Not Hispanic or Latino", "Occupations", "Outcome", "Patients", "Phase", "Philadelphia", "Population", "Poverty", "Provider", "Public Health", "Radio", "Reach Effectiveness Adoption Implementation and Maintenance", "Reduce health disparities", "Reporting", "Research", "Resource-limited setting", "Resources", "Respondent", "Rest", "Risk", "Sampling", "Services", "Site", "Social Conditions", "Social Work", "Stress", "Supervision", "Surveys", "Symptoms", "Syndrome", "Testing", "Time", "Training", "Woman", "barrier to care", "base", "bilingualism", "clinical anxiety", "cohort", "community engaged research", "community intervention", "community setting", "cost", "cost effective", "cultural competence", "design", "disparity reduction", "effectiveness testing", "experience", "follow-up", "health care availability", "health disparity", "improve minority health", "improved", "informant", "member", "men", "novel", "outreach", "peer", "post-COVID-19", "post-traumatic stress", "programs", "psychological distress", "racism", "recruit", "screening", "social stigma", "syndemic" ], "approved": true } }, { "type": "Grant", "id": "10593", "attributes": { "award_id": "1R01HS028978-01", "title": "Learning from Hospital Preparedness during COVID: Chronically Under-Resourced Nurses and Patient Safety", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 25171, "first_name": "Monika", "last_name": "Haugstetter", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-06", "end_date": "2025-08-31", "award_amount": 399292, "principal_investigator": { "id": 26621, "first_name": "Karen Blanchette", "last_name": "Lasater", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Learning from Hospital Preparedness during COVID: Chronically Under-Resourced Nurses and Patient Safety This study will evaluate how hospital nurses weathered the COVID-19 public health emergency, whether and to what extent hospital nurse resources (staffing, work environment, Magnet designation) buffered nurses from poor outcomes (such as burnout) during the pandemic and facilitated recovery 3 years after the onset of the COVID emergency, and the extent to which patient outcomes, safety, quality, and value of care indicators paralleled changes in nurse outcomes and hospital nurse resources over the study period. We will accomplish these objectives by leveraging already existing data from over 33,000 hospital nurses in 244 hospitals in New York and Illinois, [Wave 1 data collected just before COVID (Dec 2019-Feb 2020); Wave 2 collected 1 year after COVID onset] and by conducting primary data collection of repeat measures [Wave 3 to be collected 3 years after COVID onset (Oct 2022-Dec 2022)]. Each Wave includes repeated measures of nurse outcomes (e.g., burnout, job dissatisfaction, intent to leave job), hospital nurse resources (staffing, work environment, Magnet), measures of patient safety and quality of care, including items from the AHRQ Patient Safety Culture survey. These cross-sections of data will be linked with contemporaneous (1) patient-level data from CMS MedPAR Medicare to study risk-adjusted patient outcomes among patients hospitalized for common medical, surgical, and COVID diagnoses; (2) Hospital Compare data to evaluate hospital-level measures of patient satisfaction and healthcare value (Medicare spending per beneficiary), (3) American Hospital Association data for considering organizational features of hospitals, and (4) publicly available COVID hospitalization data to account for variation in COVID burden across hospitals. In combination, we will have 3 cross-sections of data from 244 hospitals (with fluctuating nurse and patient populations) just before, 1 year and 3 years after the onset of the COVID emergency. Our analytic approach uses multi-level nested (hierarchically-related) linear and logistic regression models (with interaction terms). The COVID emergency offers a unique opportunity to make a major advance in our scientific understanding of the potentially causal relationships between nurse outcomes and patient outcomes, which have until now largely only been rigorously evaluated in the cross- section. The tremendous shock imposed by the COVID emergency, combined with our propitiously timed data, enable us to evaluate how the pandemic impacted hospital nurses and what hospital factors contribute to a more favorable recovery in the years following the COVID emergency. Together, this evidence will inform high- impact actionable policy and organizational solutions for building and sustaining safe, high value healthcare systems that can endure future public health emergencies and thrive during ordinary times.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10665", "attributes": { "award_id": "1R01HD107140-01A1", "title": "Maternal SARS-CoV-2 infection, placenta biology, and neurodevelopmental outcomes in the offspring", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 6155, "first_name": "Sai Prasanna", "last_name": "Majji", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-05", "end_date": "2027-07-31", "award_amount": 757935, "principal_investigator": { "id": 26726, "first_name": "Gianluca", "last_name": "Ursini", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1954, "ror": "", "name": "LIEBER INSTITUTE, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "The extent to which SARS-CoV-2 infection in pregnancy affects the biology of the maternal-placental-fetal triad and neurodevelopmental trajectory in offspring is not known. Early studies indicate that SARS-CoV-2 can induce alterations in the placenta which can increase risk for adverse perinatal outcomes and, based on knowledge from other infectious and inflammatory disorders in pregnancy and preliminary data on the current pandemic, increase risk for neurodevelopmental disorders (NDDs) in offspring. The long-term goal of this proposal is to timely identify the impact of the ongoing pandemic on the neurodevelopment of infants born following maternal SARS-CoV-2 infection. The objective is to analyze the relationships between maternal SARS-CoV-2 infection, placenta biology, and neurodevelopmental outcomes, in interaction with genomic risk (GRSs) for NDDs and sex. The central hypothesis is that maternal SARS-CoV-2 infection and infection-related pregnancy complications affect early paths of brain development, particularly in those with high GRSs for NDDs and in males, and that these effects are mediated by alterations in placenta morphology and molecular biology. The rationale underlying the proposal is that completion will define critical targets for identification and potentially prevention of NDDs in the offspring of infected mothers. The central hypothesis will be tested by pursuing the following specific aims: 1) Determine pregnancy, placental, and newborn outcomes following antenatal SARS-CoV-2 infection; 2) Investigate the relationship between SARS-CoV-2 maternal infection, GRSs for NDDs, and placenta molecular biology; 3) Evaluate the relationship between maternal SARS-CoV-2 infection in pregnancy, offspring genomic risk factors for NDDs, and neurodevelopmental outcomes. We will pursue the aims using an innovative combination of placenta tissue and maternal and fetal blood analysis, and comprehensive psychometric testing of early child neurodevelopment. We will compare woman-placenta-infant triads exposed to SARS-CoV-2 infection during pregnancy to unvaccinated and vaccinated controls. We will study how, in a large sample of multiple ethnicities, maternal infection and stress, GRSs for NDDs, and sex, adversely affect neurodevelopmental outcomes of the offspring though processes mediated by alteration in placenta gene/protein expression and maternal immune activation. The proposed research is significant, because it will characterize the relationship between maternal SARS-CoV-2 infection and neurodevelopmental outcome of the offspring, and also identify factors, molecules and genomic predictors that modulate, mediate or – as biomarkers – reveal such relationship. The proximate expected outcome of this work will be an understanding of the mechanisms through which maternal infection, genomic risk and sex, placenta biology, and postnatal factors may contribute to define risk for NDDs. The results will have an immediate positive impact to inform targeted interventions and guidelines for SARS-CoV-2 exposed women and their infants, impacting how clinicians evaluate and care for these cases, and to identify potential biomarkers of risk for NDDs in offspring of mothers with infection during pregnancy.", "keywords": [ "2019-nCoV", "Affect", "Age", "Age-Months", "Attention deficit hyperactivity disorder", "Biological Markers", "Biology", "Birth", "Blood Vessels", "Brain", "COVID-19 pandemic", "Caring", "Cerebrum", "Child", "Child Support", "Childhood", "Clinical", "Control Groups", "Data", "Development", "Discipline of obstetrics", "Disease", "Disease Outbreaks", "Educational Intervention", "Environment", "Ethnic Origin", "Evaluation", "Event", "Exhibits", "Fetal Development", "Fetal Growth", "Fever", "First Pregnancy Trimester", "Fostering", "Future", "Gene Expression", "Gene Proteins", "Genomics", "Gestational Age", "Goals", "Guidelines", "Hospitals", "Hyperthermia", "Individual", "Infant", "Infection", "Inflammatory", "Intervention", "Knowledge", "Link", "Maternal Health", "Mediating", "Mission", "Molecular Biology", "Mothers", "Neonatal", "Neurodevelopmental Disorder", "Neurology", "Newborn Infant", "Outcome", "Pathology", "Peptides", "Placenta", "Placental Biology", "Pre-Eclampsia", "Pregnancy", "Pregnancy Complications", "Pregnancy Histories", "Pregnant Women", "Premature Birth", "Prevention", "Process", "Proteomics", "Psychometrics", "Public Health", "RNA", "Readiness", "Recovery", "Research", "Risk", "Risk Factors", "SARS-CoV-2 exposure", "SARS-CoV-2 infection", "SARS-CoV-2 positive", "Sampling", "Schizophrenia", "Second Pregnancy Trimester", "Severities", "Stress", "Testing", "Therapeutic Intervention", "Time", "Tissues", "Triad Acrylic Resin", "United States National Institutes of Health", "Vaccinated", "Vertical Disease Transmission", "Virus Diseases", "Woman", "Work", "adverse pregnancy outcome", "antenatal", "autism spectrum disorder", "base", "cohort", "congenital infection", "experience", "fetal", "fetal blood", "follow-up", "genomic predictors", "immune activation", "improved", "in utero", "innovation", "male", "maternal stress", "neurodevelopment", "offspring", "pandemic disease", "perinatal outcomes", "placental morphology", "post SARS-CoV-2 infection", "postnatal", "potential biomarker", "prenatal", "prenatal exposure", "preventive intervention", "programs", "protein expression", "recruit", "sex", "single-cell RNA sequencing", "unvaccinated" ], "approved": true } }, { "type": "Grant", "id": "10657", "attributes": { "award_id": "1R01DA057605-01", "title": "Rapid Actionable Data for Opioid Response in Kentucky (RADOR-KY)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 26700, "first_name": "SATOKO JANET", "last_name": "Kuramoto-Crawford", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-30", "end_date": "2025-09-29", "award_amount": 3125772, "principal_investigator": { "id": 26715, "first_name": "Svetla Stefanova", "last_name": "Slavova", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26716, "first_name": "Jeffery C", "last_name": "Talbert", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1162, "ror": "https://ror.org/02k3smh20", "name": "University of Kentucky", "address": "", "city": "", "state": "KY", "zip": "", "country": "United States", "approved": true }, "abstract": "Opioid use disorder (OUD) remains a persistent public health crisis and epidemic. In spite of robust national, state, and local public health responses to the epidemic, opioid overdose deaths continue to increase; of the 91,799 drug overdose deaths in 2020, reported by the Centers for Disease Control and Prevention (CDC), the majority, 68,630 (75%) involved opioids, a 38% increase from 2019. The opioid overdose death burden in Kentucky is even higher, with a 63% increase from 2019 (n=1,036) to 2020 (n=1,688). In the context of the dynamically changing opioid epidemic, complicated by the challenges presented by the COVID-19 pandemic, agencies and organizations responsible for monitoring and improving the health of the population need timely state and local data to make critical decisions on resource allocation and targeted responses. Such decisions are typically related to a set of evidence-based practices (EBPs) aimed at preventing opioid overdose mortality. We will harness the infrastructure and methodological expertise at the University of Kentucky (UK) research centers (incl. the Kentucky Injury Prevention and Research Center, the Center on Drug and Alcohol Research, and the Institute for Biomedical Informatics), along with the experience gained from our work on the HEALing Communities Study supported by the National Institute on Drug Abuse, and the Overdose Data to Action project sponsored by the CDC. The specific aims of this project are to establish the Rapid Actionable Data for Opioid Response in Kentucky (RADOR-KY)– an integrated, population-based, near-real time statewide surveillance system that will ingest data from multiple state agencies and implement advanced informatics algorithms for fast data processing, data linkage, machine learning and predictive analytics to shorten the time between data capture and when analytical results are available to support opioid overdose prevention and control. RADOR-KY will have mobile and web-based applications to provide immediate dissemination and access to near-real time community or state level data, reports, and visual analytics to share with agencies and community end-users. RADOR-KY End-user Advisory Group, including partners in state government and local communities, will guide the development of the RADOR-KY reporting and visualization functionality. RADOR- KY will establish a longitudinal dataset accessible thru the RADOR-KY portal and also shared within the HEAL Data Ecosystem. Programming code for implemented algorithms and web-based dashboards will be shared in a public repository to advance the efforts to mitigate the opioid epidemic across the U.S.", "keywords": [ "Agreement", "Algorithms", "Area", "COVID-19 pandemic", "Centers for Disease Control and Prevention (U.S.)", "Code", "Communities", "County", "Data", "Data Linkages", "Data Reporting", "Development", "Environment", "Epidemic", "Evidence based practice", "Evidence based treatment", "Goals", "Harm Reduction", "Health", "Heterogeneity", "Informatics", "Information Systems", "Infrastructure", "Intervention", "Kentucky", "Link", "Machine Learning", "Measures", "Methodology", "Monitor", "Morbidity - disease rate", "National Institute of Drug Abuse", "Online Systems", "Opioid", "Outcome", "Overdose", "Persons", "Pharmaceutical Preparations", "Policy Maker", "Population Surveillance", "Predictive Analytics", "Prevention", "Prevention Research", "Public Health", "Randomized Clinical Trials", "Recovery", "Reporting", "Research", "Research Institute", "Resource Allocation", "Risk", "State Government", "Statistical Models", "Stimulant", "System", "Thinness", "Time", "Universities", "Visual", "Visualization", "Visualization software", "Waiting Lists", "Work", "addiction", "alcohol research", "base", "biomedical informatics", "computerized data processing", "dashboard", "data ecosystem", "data ingestion", "data quality", "experience", "healing", "improved", "informatics infrastructure", "injury prevention", "longitudinal dataset", "mortality", "multiple datasets", "next generation", "opioid epidemic", "opioid exposure", "opioid mortality", "opioid overdose", "opioid use disorder", "overdose death", "overdose prevention", "population based", "population health", "prevent", "public repository", "response", "trend" ], "approved": true } }, { "type": "Grant", "id": "10545", "attributes": { "award_id": "1R43GM146542-01A1", "title": "DNA-based assay for calorimetric determination and quantitation of protein concentrations in pure or mixed solutions", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 4802, "first_name": "Fei", "last_name": "Wang", "orcid": null, "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 686, "ror": "", "name": "Joan and Sanford I. Weill Medical College of Cornell University", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] } ], "start_date": "2022-09-06", "end_date": "2023-06-05", "award_amount": 258625, "principal_investigator": { "id": 26556, "first_name": "Matthew Walter", "last_name": "Eskew", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1942, "ror": "", "name": "THERMOCAP LABORATORIES INC.", "address": "", "city": "", "state": "OR", "zip": "", "country": "United States", "approved": true }, "abstract": "An attractive feature of using in vitro expression systems to generate biological compounds is the capability to produce a wide variety of compounds (proteins, peptides, antibodies) on various scales, in a cheap and rapid manner. Current methods to analyze any of these produced compounds require purification which poses a major drawback for working with products derived from expression systems. For example, a moderately abundant (soluble) protein can require 27 individual steps over four days to purify; a significant amount of time and expense to screen a single protein. Screening a library of potential biological compounds for therapeutic value, requires many purification steps for each compound before any analysis can be performed. This includes measurements as simple as determination of the mass of the produced biological compounds. To this end we have developed a unique DNA-based scheme using differential scanning calorimetry for determination of the masses of biological compounds in both purified and mixed media. Uniquely, our probes are universally applicable to a wide range of biological compounds enabling mass quantification prior to purification. This advance allows for initial analysis of biologics early in the production process, lowering associated time requirements and resource costs. An added benefit is the possibility to supplant the numerous mass analysis kits currently on the market that rely on colorimetric or fluorescent methods. These methods are highly specific to the types of compounds assayed and have limitations preventing universal applicability. Our product offers a superior advantage of existing methods. In this project we plan to screen a library of biologically expressed SARS-CoV-2 spike and nucleocapsid proteins generated by our commercial collaborator. The aim of this work is to evaluate whether our assay is capable of predicting protein yields from their expression systems solely from a mass determination of their unpurified samples. Additionally, we will use our assay to verify the protein structure before and after purification.", "keywords": [ "2019-nCoV", "ACE2", "Address", "Antibodies", "Biological", "Biological Assay", "Biological Products", "Buffers", "Characteristics", "Clinical Trials", "Collaborations", "Complex", "Complex Mixtures", "Consumption", "Culture Media", "DNA", "Diagnostic Reagent Kits", "Differential Scanning Calorimetry", "Engineering", "Environment", "Equipment", "Feedback", "Fluorescence", "Glass", "In Vitro", "Individual", "Instruction", "Laboratories", "Libraries", "Mass Spectrum Analysis", "Measurement", "Methods", "Modification", "Molecular Target", "Nucleocapsid Proteins", "Outcome", "Pain", "Peptide antibodies", "Peptides", "Pharmaceutical Preparations", "Phase", "Process", "Production", "Property", "Protein Analysis", "Proteins", "Reagent", "Resources", "Sampling", "Scanning", "Scheme", "Surveys", "System", "Techniques", "Testing", "Therapeutic", "Thermodynamics", "Time", "Vial device", "Viral Proteins", "Work", "base", "cost", "data reduction", "design", "experience", "instrument", "melting", "novel", "novel therapeutics", "prevent", "protein structure", "response", "screening", "validation studies" ], "approved": true } }, { "type": "Grant", "id": "10537", "attributes": { "award_id": "272201700061C-P00009-9999-2", "title": "COVID-19: External Quality Assurance Program Oversight Laboratory (EQAPOL)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2023-09-29", "award_amount": 1787600, "principal_investigator": { "id": 24151, "first_name": "THOMAS", "last_name": "DENNY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "The mission of the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), is to increase basic knowledge of the pathogenesis and transmission of the human immunodeficiency virus (HIV), support the development of therapies for HIV infection and its complications, and support the development of vaccines and other prevention strategies. Reliable laboratory data are essential to the clinical evaluation of candidate HIV vaccine platforms and immunogens. Data from multiple laboratories performing assays in support of single or multiple vaccine candidate trials must be accurate and reproducible. The purpose of the External Quality Assurance Program Oversight Laboratory (EQAPOL) is to provide confidence that individual laboratories generate reliable data to support HIV vaccine immunogen advancement. EQAPOL supports these efforts by participating in the development and availability of validated assays, providing common and well-characterized reagents and Standard Operating Procedures (SOPs), and providing External Quality Assurance (EQA) programs to measure and monitor laboratory performance. This project will provide external quality assurance program support for laboratories performing immunology assays for COVID-19 Prevention Network (CoVPN)-led vaccine efficacy trials.", "keywords": [ "2019-nCoV", "Acquired Immunodeficiency Syndrome", "Antigens", "Binding", "Biological Assay", "Biometry", "COVID-19", "COVID-19 Prevention Network", "COVID-19 assay", "Data", "Development", "Flow Cytometry", "HIV", "HIV Infections", "HIV vaccine", "Immunology", "Immunology procedure", "Individual", "Knowledge", "Laboratories", "Measures", "Mission", "Monitor", "National Institute of Allergy and Infectious Disease", "Pathogenesis", "Performance", "Prevention strategy", "Procedures", "Reagent", "Reproducibility", "SARS-CoV-2 antibody", "Stains", "United States National Institutes of Health", "cytokine", "data management", "data quality", "design", "efficacy trial", "programs", "quality assurance", "reagent standard", "repository", "research clinical testing", "therapy development", "transmission process", "vaccine candidate", "vaccine development", "vaccine efficacy", "vaccine platform" ], "approved": true } }, { "type": "Grant", "id": "10569", "attributes": { "award_id": "1DP5OD033362-01", "title": "Self-Assembling Spike-EBR Nanoparticles as a Vaccine Platform Technology Against SARS-CoV-2 and Future Pandemic Coronaviruses.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Dental and Craniofacial Research (NIDCR)", "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 23244, "first_name": "Becky", "last_name": "Miller", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-15", "end_date": "2027-08-31", "award_amount": 421000, "principal_investigator": { "id": 26589, "first_name": "Magnus Adrian Gero", "last_name": "Hoffmann", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 211, "ror": "https://ror.org/05dxps055", "name": "California Institute of Technology", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic represents the 3rd outbreak caused by zoonotic transmission of a beta-coronavirus (beta-CoV) in the last 20 years. Hence there is an urgent need for new vaccine strategies to control the ongoing pandemic and prevent future CoV outbreaks. mRNA vaccines have emerged as an ideal platform for the development of rapid-response vaccines, but clinical studies have shown that neutralizing antibody titers elicited by mRNA vaccines are ~10-fold lower than titers elicited by protein nanoparticle (NP) vaccines. This is a concern with regards to the emergence of SARS-CoV-2 variants of concern (VOCs) that are less sensitive to vaccine- induced antibodies. In addition, less than 25% of the world population is fully vaccinated. Thus, rapid-response vaccine technologies are needed that elicit potent antibody responses with a single injection and/or lower doses, to ensure lasting protection against VOCs, reduce costs, and accelerate global distribution. Moreover, prevention of future CoV pandemics requires the development of a universal CoV vaccine that elicits cross-reactive immune responses against a broad spectrum of CoV strains by focusing responses to conserved epitopes. The scope of the proposed research is to design and evaluate new vaccine strategies to enhance the potency of mRNA-based rapid-response vaccines and facilitate universal CoV vaccine development. The proposal is based on the EBR NP technology, which modifies membrane proteins such as CoV spike (S) proteins to self-assemble into virus- resembling NPs that bud from the cell surface. NP assembly is induced by inserting a short amino acid sequence into the cytoplasmic tail designed to recruit proteins from the endosomal sorting complex required for transport (ESCRT) pathway. Initial studies in mice showed that low-dose injections of EBR NPs presenting the SARS- CoV-2 S protein elicited 10-fold higher neutralizing antibody titers than soluble S protein and protein-based NPs that displayed the receptor-binding domain (RBD) of the S protein. The EBR NP technology will be applied to accomplish three goals: i) Design a hybrid mRNA vaccine encoding the modified SARS-CoV-2 S-EBR construct that would be expressed at the cell surface and self-assemble into virus-resembling NPs to elicit more potent antibody responses than the approved Pfizer/Moderna vaccines, while retaining the manufacturing properties and T-cell activation of mRNA vaccines. ii) Engineer S-EBR NPs to package and deliver S or S-EBR mRNA vaccines as an alternative to lipid NPs. This delivery approach would enhance mRNA vaccine potency as S proteins presented on S-EBR NPs induce potent antibody responses, facilitate efficient intracellular delivery, and target mRNA vaccines to tissues that are naturally infected by SARS-CoV-2 to induce local immune responses. iii) Design and evaluate mosaic S-EBR NP-based universal CoV vaccine candidates that present full-length membrane-associated S proteins from multiple CoV strains to elicit cross-reactive immune responses against a broad spectrum of CoVs and protect against future outbreaks. The proposed vaccine strategies could have direct impact on the COVID-19 global health crisis and advance our emergency preparedness for the next pandemic.", "keywords": [ "2019-nCoV", "Amino Acid Sequence", "Antibody Response", "Antibody titer measurement", "Applications Grants", "Award", "B-Cell Activation", "Binding Proteins", "COVID-19 pandemic", "Cell surface", "Cells", "Clinical", "Clinical Research", "Collaborations", "Combined Vaccines", "Complex", "Coronavirus spike protein", "Cytoplasmic Tail", "Development", "Disease Outbreaks", "Dose", "Educational process of instructing", "Emergency Situation", "Encapsulated", "Engineering", "Ensure", "Epitopes", "Faculty", "Financial Support", "Funding", "Future", "Goals", "HIV-1", "Health", "Human", "Hybrids", "Immune", "Immune response", "Immunity", "Individual", "Infection", "Injections", "Institutes", "Job Application", "Laboratories", "Length", "Liquid substance", "Membrane", "Membrane Proteins", "Mentors", "Messenger RNA", "Monoclonal Antibodies", "Mosaicism", "Mus", "Pathway interactions", "Persons", "Population", "Prevention", "Production", "Property", "Protein Binding Domain", "Proteins", "RNA vaccine", "RNA-Protein Interaction", "Readiness", "Research", "Research Personnel", "Robot", "SARS-CoV-2 spike protein", "SARS-CoV-2 variant", "Sorting - Cell Movement", "System", "T-Cell Activation", "Technology", "Therapeutic", "Tissues", "Translational Research", "Vaccinated", "Vaccines", "Virus", "Zoonoses", "base", "betacoronavirus", "cost", "cost effective", "cross reactivity", "design", "graduate student", "in vivo", "industry partner", "invention", "lipid nanoparticle", "low income country", "mRNA delivery", "member", "nanoparticle", "neutralizing antibody", "novel vaccines", "pandemic coronavirus", "pandemic disease", "preclinical development", "preclinical study", "prevent", "programs", "receptor binding", "recruit", "response", "student mentoring", "transmission process", "universal coronavirus vaccine", "vaccine candidate", "vaccine delivery", "vaccine development", "vaccine platform", "vaccine response", "vaccine strategy", "vaccine-induced antibodies", "variants of concern" ], "approved": true } } ], "meta": { "pagination": { "page": 3, "pages": 1442, "count": 14420 } } }